

EZ-SARS-CoV-2 Real-Time RT-PCR Performance Characteristics

For the qualitative detection of SARS-CoV-2 viral RNA
extracted from mid-turbinate nasal swab specimens

Catalog Number TC-5048-192

For *In Vitro* Diagnostic Use
Rx Only

Distributed in accordance with the guidance on
*Policy for Coronavirus Disease-2019 Tests During the Public Health
Emergency, Section IV.C.2.*



Tetracore has filed for Emergency Use Authorization (EUA) with the US FDA. The test has been validated by Tetracore, but the US FDA's independent review of this validation is pending.

Performance Characteristics

Limit of Detection (LoD) - Analytical Sensitivity

The LoD study established the lowest detectable concentration of SARS-CoV-2 (genomic copy equivalents or GCE) at which approximately 95% of all (true positive) replicates test positive with the EZ-SARS-CoV-2 Real-Time RT-PCR. Mid-turbinate nasal swab specimens collected in 1 mL sterile saline obtained from individuals who tested negative for SARS-CoV-2 were pooled and spiked with gamma-irradiated SARS-Related Coronavirus 2, Isolate USA-WA1/2020 (BEI Resources NR-52287). The pooled clinical matrix was screened negative using the EZ-SARS-CoV-2 Real-Time RT-PCR prior to spiking. Serial dilutions of SARS-CoV-2 were made in the clinical matrix and tested in three replicates. Each viral dilution was added to three swabs (50 μ L per swab head). The swabs were each collected in 1 mL sterile saline and then processed through the EZ-SARS-CoV-2 Real-Time RT-PCR workflow, including nucleic acid extraction using the Qiagen QIAamp[®] Viral RNA Mini Kit following the manufacturer's recommended procedure with the Inhibition Control added to the lysis buffer. Real-time PCR for the EZ-SARS-CoV-2 Real-Time RT-PCR was carried out on the Applied Biosystems 7500 Fast Real-Time PCR System and the T-COR 8[™] Real-Time PCR Thermocycler. The lowest concentration at which all three replicates were positive was treated as the preliminary LoD for each real-time PCR instrument. The preliminary LoD was determined to be 3 GCE per reaction for both real-time PCR instruments (see Tables 1 and 2).

Table 1. Preliminary LoD study on the ABI 7500 Fast.

| Effective Concentration | Replicate | SARS-CoV-2 Ct Value | IC Ct Value | RNase P Ct Value | Detection Rate |
|-------------------------|-----------|---------------------|-------------|------------------|----------------|
| 300 GCE/reaction | 1 | 28.6 | 26.8 | 29.2 | 100% |
| | 2 | 28.7 | 26.6 | 29.2 | |
| | 3 | 28.4 | 26.9 | 29.1 | |
| 100 GCE/reaction | 1 | 30.2 | 26.5 | 29.2 | 100% |
| | 2 | 30.3 | 27.1 | 29.1 | |
| | 3 | 30.0 | 27.0 | 29.2 | |
| 30 GCE/reaction | 1 | 32.0 | 27.2 | 29.1 | 100% |
| | 2 | 31.9 | 27.0 | 29.1 | |
| | 3 | 31.8 | 27.1 | 29.5 | |
| 10 GCE/reaction | 1 | 33.7 | 27.2 | 29.1 | 100% |
| | 2 | 34.2 | 26.9 | 29.4 | |
| | 3 | 33.8 | 27.0 | 29.1 | |
| 3 GCE/reaction | 1 | 34.9 | 26.6 | 29.2 | 100% |
| | 2 | 35.5 | 27.0 | 29.3 | |
| | 3 | 36.2 | 26.8 | 29.3 | |
| 1 GCE/reaction | 1 | - | 27.0 | 29.2 | 66.7% |
| | 2 | 36.7 | 27.2 | 29.6 | |
| | 3 | 36.7 | 27.2 | 29.1 | |
| 0.3 GCE/reaction | 1 | - | 26.7 | 29.5 | 0% |
| | 2 | - | 26.8 | 29.3 | |
| | 3 | - | 26.9 | 29.3 | |

Table 2. Preliminary LoD study on the T-COR 8™.

| Effective Concentration | Replicate | SARS-CoV-2 Ct Value | IC Ct Value | RNase P Ct Value | Detection Rate |
|-------------------------|-----------|---------------------|-------------|------------------|----------------|
| 300 GCE/reaction | 1 | 30.7 | 28.3 | 30.3 | 100% |
| | 2 | 31.0 | 28.3 | 30.2 | |
| | 3 | 30.7 | 28.9 | 30.4 | |
| 100 GCE/reaction | 1 | 32.9 | 28.7 | 30.5 | 100% |
| | 2 | 32.3 | 28.8 | 30.5 | |
| | 3 | 32.1 | 28.7 | 30.4 | |
| 30 GCE/reaction | 1 | 34.1 | 28.9 | 30.6 | 100% |
| | 2 | 33.7 | 28.8 | 30.1 | |
| | 3 | 34.2 | 28.9 | 30.9 | |
| 10 GCE/reaction | 1 | 35.2 | 28.6 | 30.2 | 100% |
| | 2 | 35.7 | 28.8 | 30.6 | |
| | 3 | 35.8 | 28.8 | 30.3 | |
| 3 GCE/reaction | 1 | 36.9 | 28.6 | 30.5 | 100% |
| | 2 | 36.8 | 28.7 | 30.7 | |
| | 3 | 36.1 | 28.8 | 30.9 | |
| 1 GCE/reaction | 1 | - | 28.8 | 30.8 | 66.7% |
| | 2 | 37.5 | 29.0 | 30.7 | |
| | 3 | 38.0 | 29.0 | 30.8 | |
| 0.3 GCE/reaction | 1 | - | 28.5 | 30.9 | 0% |
| | 2 | - | 28.7 | 30.7 | |
| | 3 | - | 28.8 | 30.6 | |

The confirmatory LoD study was performed in the same manner as the preliminary LoD study described above. Twenty replicates were tested at the preliminary LoD of 3 GCE per reaction on the ABI 7500 Fast and T-COR 8™ real-time PCR instruments (see Tables 3 and 4). The LoD was determined to be 3 GCE per reaction for both real-time PCR instruments.

Table 3. Confirmatory LoD study on the ABI 7500 Fast.

| Effective Concentration | Replicate | SARS-CoV-2 Ct Value | IC Ct Value | RNase P Ct Value | Detection Rate |
|-------------------------|-----------|---------------------|-------------|------------------|----------------|
| 3 GCE/reaction | 1 | 35.0 | 27.0 | 29.1 | 100% |
| | 2 | 35.0 | 26.6 | 29.1 | |
| | 3 | 35.2 | 26.6 | 29.4 | |
| | 4 | 35.1 | 26.2 | 29.0 | |
| | 5 | 34.7 | 26.6 | 29.1 | |
| | 6 | 35.6 | 26.4 | 29.0 | |
| | 7 | 35.6 | 26.7 | 29.1 | |

| | | | | | |
|--|----|------|------|------|--|
| | 8 | 34.8 | 26.6 | 29.0 | |
| | 9 | 35.0 | 26.5 | 29.0 | |
| | 10 | 34.4 | 26.7 | 29.0 | |
| | 11 | 34.9 | 26.6 | 29.0 | |
| | 12 | 36.1 | 26.6 | 29.1 | |
| | 13 | 34.8 | 26.4 | 29.2 | |
| | 14 | 36.2 | 26.3 | 29.1 | |
| | 15 | 35.3 | 26.4 | 29.0 | |
| | 16 | 36.0 | 26.5 | 29.1 | |
| | 17 | 34.7 | 26.6 | 29.1 | |
| | 18 | 34.2 | 26.6 | 29.0 | |
| | 19 | 36.8 | 26.7 | 29.3 | |
| | 20 | 34.9 | 26.4 | 29.0 | |

Table 4. Confirmatory LoD study on the T-COR 8™.

| Effective Concentration | Replicate | SARS-CoV-2 Ct Value | IC Ct Value | RNase P Ct Value | Detection Rate |
|-------------------------|-----------|---------------------|-------------|------------------|----------------|
| 3 GCE/reaction | 1 | 36.5 | 28.7 | 30.0 | 100% |
| | 2 | 37.0 | 28.8 | 30.4 | |
| | 3 | 36.1 | 28.8 | 30.8 | |
| | 4 | 36.9 | 28.6 | 30.6 | |
| | 5 | 37.1 | 28.9 | 30.5 | |
| | 6 | 36.3 | 28.4 | 30.5 | |
| | 7 | 36.0 | 28.8 | 30.5 | |
| | 8 | 37.5 | 28.9 | 30.5 | |
| | 9 | 36.5 | 28.8 | 30.4 | |
| | 10 | 37.5 | 28.7 | 30.4 | |
| | 11 | 36.0 | 28.3 | 30.2 | |
| | 12 | 37.5 | 28.5 | 30.5 | |
| | 13 | 35.7 | 28.3 | 30.5 | |
| | 14 | 36.7 | 28.3 | 30.6 | |
| | 15 | 37.4 | 28.4 | 30.5 | |
| | 16 | 36.6 | 28.7 | 30.5 | |
| | 17 | 36.2 | 28.6 | 30.5 | |
| | 18 | 36.5 | 28.4 | 30.3 | |
| | 19 | 36.9 | 28.7 | 30.6 | |
| | 20 | 36.4 | 28.5 | 30.4 | |

Inclusivity (*In Silico* Analysis)

The original *in silico* analysis utilized sequences available early in the pandemic. The nucleotide mismatch frequency of the EZ-SARS-CoV-2 Real-Time RT-PCR N gene primer and probe sequences was evaluated using GISAID sequences (<https://www.gisaid.org>) downloaded on August 4, 2020. The dataset includes 76,047 SARS-CoV-2 sequences collected from December 24, 2019 through July 2020. The combined assay (including all N gene targets) matches >99.5% of all sequences. One mismatch in one of the N gene assay probe sequences is a single point of divergence from 99.5% inclusivity. After filtering for completeness, 2.24% of the sequences (1,649) showed the mismatch. Because the EZ-SARS-CoV-2 Real-Time RT-PCR utilizes a single reporter dye (FAM) for detection of all N gene targets, mismatches would need to be present in all N gene assay regions to produce a false negative result. Twenty four of the SARS-CoV-2 sequences contain a mismatch in each of the EZ-SARS-CoV-2 Real-Time RT-PCR N gene assay regions. None of these 24 sequences were found to have more than one mismatch in any single N gene assay region. Because the EZ-SARS-CoV-2 Real-Time RT-PCR is expected to tolerate a single mismatch greater than 5 bases from the 3' end of a primer or a single mismatch in a probe, none of the SARS-CoV-2 sequences are anticipated to produce a false negative result.

Updated *in silico* analyses are performed on a regular basis evaluating the mismatch frequency of the N gene primer and probe sequences using SARS-CoV-2 sequences in the GISAID database. To date, the assessment of homology between these SARS CoV-2 sequences shows that the risk of significant loss of signal amplification and/or false negative results is very low due to the absence of a significant numbers of mismatches.

Cross-reactivity (Analytical Specificity)**In Silico Analysis**

BLASTn analysis queries of the EZ-SARS-CoV-2 Real-Time RT-PCR assays primers and probes were performed against public domain nucleotide sequences. The database search parameters were as follows: 1) The nucleotide collection consists of GenBank NT and RefSeq sequences, but excludes EST, STS, GSS, WGS, TSA, patent; 2) The database is non-redundant. Identical sequences have been merged into one entry, while preserving the accession, GI, title and taxonomy information for each entry; 3) Database(s) was updated on 08/15/2021; 4) The search parameters automatically adjust for short input sequences and the expected threshold is 1000; 5) The match and mismatch scores are 1 and -3, respectively. Additionally, Needleman–Wunsch alignments were performed against a defined set of data containing all the sequences in Table 5.

Each primer and probe was aligned to the sequences listed in Table 5. The alignment used the Needleman Wunsch global alignment implemented by seq-align as well as NCBI BLASTn tools. No gaps were allowed in the alignment and a match matrix was used. The matrix scored the alignment with a 1 for match and a 0 for anything else. The alignment score was the number of matches between the primer or probe and the pathogen. The frequency of the alignment is the number of matches divided by the length of the primer or probe.

The probe sequence of one of the EZ-SARS-CoV-2 Real-Time RT-PCR N gene assays matches to the genome of SARS coronavirus Urbani with an identity of 96%. However, the forward and reverse primers show reduced homology (70% and 92% with two key mismatches, respectively). These primers and probe have no significant homologies with the human genome, other coronaviruses or human microflora that would predict potential for interference or false positive rRT-PCR results. The forward primer sequence of another EZ-SARS-CoV-2 Real-Time RT-PCR N gene assay showed 100% sequence identity to SARS coronavirus Urbani. The reverse primer and probe sequences showed less significant homology with SARS coronavirus Urbani, as well as the human genome, other coronaviruses or human microflora (the BLASTn expectation value was greater than 1.0).

In summary, the EZ-SARS-CoV-2 Real-Time RT-PCR N gene assays, designed for the specific detection of SARS-CoV-2, showed no significant combined homologies with the human genome, other coronaviruses, or human microflora that would predict potential false positive rRT-PCR results.

Table 5. EZ-SARS-CoV-2 Real-Time RT-PCR cross-reactivity (*in silico* analysis).

| Pathogen | Strain | GenBank Accession No. |
|-----------------------------------|--|-----------------------|
| Adenovirus | Human adenovirus type 1, complete genome | AC_000017.1 |
| <i>Bordetella pertussis</i> | <i>Bordetella pertussis</i> strain B3921, complete genome | CP011448.1 |
| <i>Candida albicans</i> | <i>Candida albicans</i> strain L757 mitochondrion, complete genome | NC_018046.1 |
| <i>Chlamydia pneumoniae</i> | <i>Chlamydia pneumoniae</i> genome assembly PB2, chromosome: 1 | NZ_LN847241.1 |
| Enterovirus | Human enterovirus 68 isolate EV68_NL_201013421 VP1 protein gene, partial cds | JF896312.1 |
| <i>Haemophilus influenzae</i> | <i>Haemophilus influenzae</i> PittGG, complete genome | CP000672.1 |
| Human coronavirus 229E | Human coronavirus 229E strain 229E/human/USA/932-72/1993, complete genome | KF514432.1 |
| Human coronavirus 229E | Human coronavirus 229E strain 229E/human/USA/933-40/1993, complete genome | KF514433.1 |
| Human coronavirus HKU1 | Human coronavirus HKU1 isolate SI17244, complete genome | MH940245.1 |
| Human coronavirus HKU1 | Human coronavirus HKU1 strain HKU1/human/USA/HKU1-18/2010, complete genome | KF430201.1 |
| Human coronavirus NL63 | Human coronavirus NL63 strain NL63/human/USA/891-4/1989, complete genome | KF530114.1 |
| Human coronavirus NL63 | Human coronavirus NL63 strain NL63/human/USA/905-25/1990, complete genome | KF530113.1 |
| Human coronavirus OC43 | Human coronavirus OC43 isolate LRTI_238, complete genome | KX344031.1 |
| Human coronavirus OC43 | Human coronavirus OC43 strain OC43/human/USA/971-5/1997, complete genome | KF530099.1 |
| Human Metapneumovirus (hMPV) | Human metapneumovirus strain HMPV/Homo sapiens/PER/FPP00726/2011/A, complete genome | KJ627437.1 |
| Influenza A | Influenza A virus (A/New York/PV305/2017(H1N1)) segment 2 polymerase PB1 (PB1) gene, complete cds and functional PB1-F2 protein (PB1-F2) gene, complete sequence | MH798556.1 |
| Influenza B | Influenza B virus (B/Nicaragua/8689_13/2017) segment 2 polymerase PB2 (PB2) gene, complete cds | MK969560.1 |
| <i>Legionella pneumophila</i> | <i>Legionella pneumophila</i> strain Philadelphia_1_CDC, complete genome | CP015928.1 |
| MERS-Coronavirus | Middle East respiratory syndrome-related coronavirus strain HcoV-EMC, complete genome | MH013216.1 |
| <i>Mycobacterium tuberculosis</i> | <i>Mycobacterium tuberculosis</i> DNA, complete genome, strain: HN-506 | AP018036.1 |
| <i>Mycoplasma pneumoniae</i> | <i>Mycoplasma pneumoniae</i> strain 14-637 chromosome, complete genome | CP039772.1 |
| Parainfluenza 1 | Human parainfluenza virus 1 isolate NM001, complete genome | KX639498.1 |
| Parainfluenza 2 | Human parainfluenza virus 2 isolate VIROAF10, complete genome | KM190939.1 |
| Parainfluenza 3 | Human parainfluenza virus 3 strain HPIV3/AUS/3/2007, complete genome | KF530243.1 |
| Parainfluenza 4 | Human parainfluenza virus 4a isolate HPIV4_DK (459), complete genome | KF483663.1 |

| | | |
|-----------------------------------|--|-------------|
| <i>Pneumocystis jirovecii</i> | Pneumocystis jirovecii isolate SW7_full mitochondrion, complete genome | MH010446.1 |
| <i>Pseudomonas aeruginosa</i> | Pseudomonas aeruginosa UCBPP-PA14, complete genome | CP000438.1 |
| Respiratory syncytial virus | Respiratory syncytial virus strain B/WI/629-Q0190/10, complete genome | JN032120.1 |
| Rhinovirus | Human rhinovirus 14, complete genome | NC_001490.1 |
| SARS-coronavirus | SARS coronavirus Urbani, complete genome | AY278741.1 |
| SARS-CoV-2 | Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome | NC_045512.2 |
| <i>Staphylococcus epidermidis</i> | Staphylococcus epidermidis strain SP3 16S ribosomal RNA gene, partial sequence | KY750253.1 |
| <i>Streptococcus pneumoniae</i> | Streptococcus pneumoniae strain D39V chromosome, complete genome | CP027540.1 |
| <i>Streptococcus pyogenes</i> | Streptococcus pyogenes MGAS8232, complete genome | AE009949.1 |
| <i>Streptococcus salivarius</i> | Streptococcus salivarius strain LAB813 chromosome, complete genome | CP040804.1 |

Wet Testing

To confirm the cross-reactivity of the EZ-SARS-CoV-2 Real-Time RT-PCR in the wet test condition, 40 non-target organisms were prepared by extracting each standard organism (concentration of $> 10^6$ CFU/mL or $> 10^4$ TCID₅₀/mL, when available from the vendor) using the Qiagen QIAamp® Viral RNA Mini Kit. Real-time PCR for the EZ-SARS-CoV-2 Real-Time RT-PCR was carried out on the Applied Biosystems 7500 Fast Real-Time PCR System and the T-COR 8™ Real-Time PCR Thermocycler. Testing was performed in triplicate on the ABI 7500 Fast, and a minimum of one replicate was tested on the T-COR 8™. As a result, all 40 non-target samples were not detected (see Table 6).

Table 6. EZ-SARS-CoV-2 Real-Time RT-PCR cross-reactivity (wet testing).

| Organism | Source | Isolate No. | Replicates Detected/Total | |
|---|---------------|-------------|---------------------------|----------|
| | | | 7500 Fast | T-COR 8™ |
| Human coronavirus 229E | Zeptomatrix | 0810229CF | 0/3 | 0/1 |
| Human coronavirus OC43 | Zeptomatrix | 0810024CF | 0/3 | 0/1 |
| Human coronavirus NL63 | BEI Resources | NR-470 | 0/3 | 0/1 |
| SARS coronavirus | BEI Resources | NR-9547 | 0/3 | 0/1 |
| MERS coronavirus | BEI Resources | NR-45843* | 0/3 | 0/1 |
| Adenovirus Type 7A | Zeptomatrix | 0810021CF | 0/3 | 0/1 |
| Adenovirus Type 1 | Zeptomatrix | 0810050CF | 0/3 | 0/1 |
| Adenovirus Type 4 | Zeptomatrix | 0810070CF | 0/3 | 0/1 |
| Human metapneumovirus (hMPV) 16 Type A1 | Zeptomatrix | 0810161CF | 0/3 | 0/1 |
| Parainfluenza virus 1 | BEI Resources | NR-48680 | 0/3 | 0/1 |
| Parainfluenza virus 2 | BEI Resources | NR-3229 | 0/3 | 0/1 |
| Parainfluenza virus 3 | BEI Resources | NR-3233 | 0/3 | 0/1 |
| Parainfluenza virus 4A | BEI Resources | NR-3237 | 0/3 | 0/1 |
| Parainfluenza virus 4B | BEI Resources | NR-3238 | 0/3 | 0/1 |
| Influenza A H1N1 | BEI Resources | NR-13663 | 0/3 | 0/1 |
| Influenza A H3N2 | BEI Resources | NR-41803 | 0/3 | 0/1 |

| | | | | |
|---|---------------|-----------|-----|-----|
| Influenza B | BEI Resources | NR-42006 | 0/3 | 0/1 |
| Enterovirus Type 68 | Zeptomatrix | 0810237CF | 0/3 | 0/1 |
| Enterovirus 71 | BEI Resources | NR-471 | 0/3 | 0/1 |
| Enterovirus D68 | BEI Resources | NR-49131 | 0/3 | 0/1 |
| Respiratory syncytial virus A1998/3-2 | BEI Resources | NR-28529 | 0/3 | 0/3 |
| Respiratory syncytial virus B1 | BEI Resources | NR-4052 | 0/3 | 0/3 |
| Respiratory syncytial virus A1998/12-21 | BEI Resources | NR-28528 | 0/3 | 0/3 |
| Rhinovirus 20, 15-CV19 | BEI Resources | NR-51439 | 0/3 | 0/1 |
| Rhinovirus 60, 2268-CV37 | BEI Resources | NR-51447 | 0/3 | 0/1 |
| Rhinovirus 34, 137-3 | BEI Resources | NR-51451 | 0/3 | 0/1 |
| <i>Chlamydia pneumoniae</i> | ATCC | 53592 | 0/3 | 0/1 |
| <i>Haemophilus influenzae</i> | ATCC | 33391 | 0/3 | 0/1 |
| <i>Legionella pneumophila</i> | Zeptomatrix | 0801645 | 0/3 | 0/1 |
| <i>Mycobacterium tuberculosis</i> | Zeptomatrix | 0801660 | 0/3 | 0/1 |
| <i>Streptococcus pneumoniae</i> | ATCC | 49619 | 0/3 | 0/1 |
| <i>Streptococcus pyogenes</i> | ATCC | 10782 | 0/3 | 0/1 |
| <i>Bordetella pertussis</i> | BEI Resources | NR-42460 | 0/3 | 0/1 |
| <i>Mycoplasma pneumoniae</i> | Zeptomatrix | 0801579 | 0/3 | 0/1 |
| <i>Pneumocystis jirovecii</i> (PJP) | ATCC | PRA-159 | 0/3 | 0/1 |
| Pooled human nasal wash | In-House | | 0/3 | 0/1 |
| <i>Candida albicans</i> | ATCC | 18804 | 0/3 | 0/1 |
| <i>Pseudomonas aeruginosa</i> | ATCC | 27853 | 0/3 | 0/1 |
| <i>Staphylococcus epidermidis</i> | ATCC | 14990 | 0/3 | 0/1 |
| <i>Streptococcus salivarius</i> | ATCC | 13419 | 0/3 | 0/1 |

*Isolate NR-45843 was received as nucleic acid extracted from a preparation of MERS-CoV, EMC/2012 (BEI Resources NR-44260) using the QIAamp® Viral RNA Mini Kit (Qiagen 52906), and was therefore not further extracted.

Clinical Evaluation

Blinded panels totaling 86 clinical specimens were tested at CLIA high-complexity laboratories which characterized the samples for SARS-CoV-2 by the use of an FDA authorized comparator SARS-CoV-2 assay. The specimens were mid-turbinate nasal swabs in sterile saline collected from patients by qualified personnel. Fifty-four of the clinical specimens had SARS-CoV-2 positive test results, and 32 had SARS-CoV-2 negative test results. The blinded specimen panel was processed through the EZ-SARS-CoV-2 Real-Time RT-PCR workflow and tested on the Applied Biosystems 7500 Fast Real-time PCR System and the T-COR 8™ Real-time PCR Thermocycler (see Tables 7 and 8). Fifty-three of the 54 specimens found to be positive for SARS-CoV-2 by the comparator assay also gave positive results when tested with the EZ-SARS-CoV-2 Real-Time RT-PCR on both the ABI 7500 Fast and the T-COR 8™. All 32 specimens found to be negative for SARS-CoV-2 by the comparator assay also gave negative results when tested with the EZ-SARS-CoV-2 Real-Time RT-PCR on both the ABI 7500 Fast and the T-COR 8™.



Table 7. Clinical performance of the EZ-SARS-CoV-2 Real-Time RT-PCR on the ABI 7500 Fast.

| EZ-SARS-CoV-2 Real-Time RT-PCR | Comparator RT-PCR Assay | | Total |
|-----------------------------------|-------------------------|-----------|-----------|
| | Positive | Negative | |
| Positive | 53 | 0 | 53 |
| Negative | 1 | 32 | 33 |
| Total | 54 | 32 | 86 |

Table 8. Clinical performance of the EZ-SARS-CoV-2 Real-Time RT-PCR on the T-COR 8™.

| EZ-SARS-CoV-2 Real-Time RT-PCR | Comparator RT-PCR Assay | | Total |
|-----------------------------------|-------------------------|-----------|-----------|
| | Positive | Negative | |
| Positive | 53 | 0 | 53 |
| Negative | 1 | 32 | 33 |
| Total | 54 | 32 | 86 |

Symbols

| Symbol | Meaning | Symbol | Meaning |
|---|---|---|--------------|
|  | <i>In Vitro</i> Diagnostic Medical Device |  | Manufacturer |

How to Obtain More Information

Tetracore, Inc.
77 Upper Rock Circle
Suite 600
Rockville, MD 20850

Tel: 240.268.5400
Fax: 240.268.1107
Email: sales@tetracore.com
www.tetracore.com

Tetracore® is a registered trademark of Tetracore, Inc.